Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279001 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Study of Jaktinib
A Phase 1 study of Myelofibrosis, sponsored by Suzhou Zelgen Biopharmaceuticals Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT05279001 is a Phase 1 study of Myelofibrosis that is actively recruiting participants, run by Suzhou Zelgen Biopharmaceuticals Co.. The registered enrollment target is 26 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05279001, a Phase 1 study of Myelofibrosis, is actively recruiting participants, sponsored by Suzhou Zelgen Biopharmaceuticals Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.
Conditions Studied
Interventions
- DRUG Jaktinib Hydrochloride Tablet
Study Locations (1)
Ohio
- Site 01 - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2025-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05279001
The ClinicalTrials.gov registry entry for NCT05279001 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (87% lower). The listed sponsor is Suzhou Zelgen Biopharmaceuticals Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Jaktinib Hydrochloride Tablet is the first listed.
NCT05279001 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05279001 about?
NCT05279001 is a clinical study titled "A Safety and Tolerability Study of Jaktinib". This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.
What is the current status of trial NCT05279001?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2024-07-01. Estimated completion is 2025-11-30.
What conditions does trial NCT05279001 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT05279001?
The interventions under investigation include: Jaktinib Hydrochloride Tablet (DRUG).
Who is sponsoring clinical trial NCT05279001?
This trial is sponsored by Suzhou Zelgen Biopharmaceuticals Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05279001 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.